Melinta on SPi NewsFollow our SPi News RSS Feed for melinta

Featured melinta News

[29 Jan 2018] Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States

[18 Jan 2018] Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis

[08 Jan 2018] Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio

[03 Jan 2018] Melinta Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

[02 Jan 2018] Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor Relations

[29 Nov 2017] The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics

[06 Nov 2017] Melinta Therapeutics Announces Successful Completion of Merger

[01 Nov 2017] Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization

[31 Oct 2017] Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company

[30 Oct 2017] Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States

[24 Oct 2017] Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities

[10 Oct 2017] Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne

[28 Sep 2017] Cempra and Melinta Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger

[09 Aug 2017] Malin Investee Company - Melinta Therapeutics - To Be Transformed into a NASDAQ Listed Company

[01 Jun 2017] Melinta Therapeutics Presenting In Vivo and In Vitro Results from Baxdela Studies at ASM Microbe

[02 May 2017] Melinta Therapeutics’ Phase 3 trials of Baxdela Document Challenges in Antibiotic Selection in Patients Treated for ABSSSI

[19 Apr 2017] Melinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017

[02 Mar 2017] Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

[28 Feb 2017] Melinta Therapeutics Announces FDA Acceptance of Investigational New Drug Application for Topical Radezolid

[27 Feb 2017] Melinta Therapeutics Provides Baxdela NDA Update

[05 Jan 2017] Melinta Therapeutics’ New Drug Application for Baxdela Accepted for Filing by US FDA

[26 Oct 2016] Melinta Therapeutics’ Baxdela™ to be Featured in Six Poster Presentations at IDWeek 2016™

[24 Oct 2016] Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections

[14 Jun 2016] Melinta Therapeutics Presenting Results from Baxdela and ESKAPE Programs at ASM Microbe 2016 Meeting

[12 May 2016] Melinta Therapeutics’ Baxdela™ Successfully Achieves Endpoints in Confirmatory Phase 3 Study in Patients with Hospital-Treated Skin Infections

[19 Apr 2016] Melinta Therapeutics Appoints Dr. Eugene Sun as Chief Executive Officer

[03 Mar 2016] Melinta Therapeutics to Present at BioCentury Future Leaders Conference

[23 Feb 2016] Melinta Therapeutics Appoints John Temperato President and Chief Operating Officer

[06 Jan 2016] Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia

[05 Jan 2016] Melinta Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference

[19 Sep 2015] Melinta Therapeutics Demonstrates Potency of Delafloxacin against Bacteria Associated with Respiratory Tract Infections

[08 Sep 2014] Melinta Therapeutics Demonstrates Potent In Vitro Activity of New Antibiotic Class against Gram Negative ESKAPE Pathogens

[06 Sep 2014] Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens

[06 Sep 2014] Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program

[04 Sep 2014] Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting

[14 Aug 2014] Melinta Therapeutics Bolsters Board of Directors with Appointment of Christopher Kiritsy

[11 Aug 2014] Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration

[24 Jul 2014] Melinta Therapeutics Announces Accepted Abstracts at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

[17 Jun 2014] Melinta Therapeutics to Present at Annual JMP Securities Healthcare Conference

Still looking?

Type in your search term below and click Enter

World News from SPi

Sector Publishing Intelligence [SPi'] publishes financial news from around the world FAST. For breaking news announcements from companies, blogs and commentators, SPi provides up to the minute, integrated news on all aspects of financial markets and financial services.

The SPi Financial News Search gets results from our extensive news archives containing 10’s of thousands of news reports. Intelligent cross referencing of stories and background gives readers and researchers highly relevant related information about topics and businesses in the finance sector.

Trending financial topics highlight the most recent themes in the news. Thousands of financial topics can be followed using RSS, or join hundreds of SPis Financial News followers on Twitter for instant news as soon as it’s published on SPi. @SPiFinancialSvc

SPi's extensive database of corporate information shows company details alongside breaking corporate news from the world’s largest news providers.

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers